CorMedix (CRMD) EBT Margin (2013 - 2026)

CorMedix (CRMD) posted EBT Margin of 43.89% for Q4 2025, down 12.96% sequentially from 50.42% in Q3 2025, and up 75.0% YoY from 25.08% in Q4 2024.

CorMedix (CRMD) EBT Margin (2013 - 2026) Analysis & Trends

CorMedix has reported EBT Margin for 12 years, with the latest figure at 43.89% in Q4 2025.

Quarterly EBT Margin rose 75.0% year-over-year to 43.89% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 48.13% (up 9255.0% YoY) and the FY2025 annual result came in at 48.13%, up 9258.0% from the prior year.
EBT Margin retreated to 43.89% in Q4 2025 per CRMD's latest filing, from 50.42% in the prior quarter.
Over five years, EBT Margin peaked at 52.82% in Q1 2025 and troughed at 106896.41% in Q1 2022.
A 4-year average of 26855.79% and a median of 13814.54% in 2021 frame the typical range for EBT Margin.
The widest YoY moves for EBT Margin: up 3328633 bps in 2022, down 8734617 bps in 2022.
Over 4 years, EBT Margin stood at 13814.54% in 2021, then slumped by 100 bps to 27637.7% in 2022, then jumped by 100 bps to 43.14% in 2024, then climbed by 2 bps to 43.89% in 2025.
According to Business Quant data, EBT Margin over the past three periods registered 43.89%, 50.42%, and 51.21% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	35.61%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	35.71%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	13.77%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-25.06%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-2.67%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	12.09%
10	CorMedix	645.20 Mn	388.51 Mn	77.13 Mn	38.00%

Download Data